Unlock stock picks and a broker-level newsfeed that powers Wall Street.
BSE - Delayed Quote INR

Nectar Lifesciences Limited (NECLIFE.BO)

Compare
24.51
-1.28
(-4.96%)
At close: April 4 at 3:50:16 PM GMT+5:30
Loading Chart for NECLIFE.BO
  • Previous Close 25.79
  • Open 26.30
  • Bid --
  • Ask 24.51 x --
  • Day's Range 24.51 - 26.30
  • 52 Week Range 21.85 - 56.39
  • Volume 120,250
  • Avg. Volume 263,583
  • Market Cap (intraday) 5.497B
  • Beta (5Y Monthly) 1.12
  • PE Ratio (TTM) 32.68
  • EPS (TTM) 0.75
  • Earnings Date May 13, 2025 - May 17, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Sep 18, 2020
  • 1y Target Est --

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

www.neclife.com

1,686

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NECLIFE.BO

View More

Performance Overview: NECLIFE.BO

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

NECLIFE.BO
37.15%
S&P BSE SENSEX (^BSESN)
3.55%

1-Year Return

NECLIFE.BO
31.29%
S&P BSE SENSEX (^BSESN)
1.53%

3-Year Return

NECLIFE.BO
8.03%
S&P BSE SENSEX (^BSESN)
24.34%

5-Year Return

NECLIFE.BO
128.27%
S&P BSE SENSEX (^BSESN)
173.15%

Compare To: NECLIFE.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NECLIFE.BO

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    5.50B

  • Enterprise Value

    11.53B

  • Trailing P/E

    32.68

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.33

  • Price/Book (mrq)

    0.51

  • Enterprise Value/Revenue

    0.69

  • Enterprise Value/EBITDA

    6.33

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.01%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    16.81B

  • Net Income Avi to Common (ttm)

    170.01M

  • Diluted EPS (ttm)

    0.75

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    187.35M

  • Total Debt/Equity (mrq)

    58.37%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: NECLIFE.BO

View More

Company Insights: NECLIFE.BO

Research Reports: NECLIFE.BO

View More

People Also Watch